Search results
Results from the WOW.Com Content Network
John E. Abele (born 1937) is an American businessman and co-founder of Boston Scientific, a medical device company. He received the ASME Medal in 2010 and, as of November 2024, has a net worth of $1.9 billion. [1] He was first listed on the Forbes 400 in 1996 as a self-made billionaire.
Boston Scientific Corporation (BSC), headquartered in Marlborough, Massachusetts and incorporated in Delaware, [2] is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular ...
They borrowed $800,000 to start Boston Scientific, a manufacturer of medical devices. He helped grow the company through a series of astute acquisitions. [6] Nicholas was chief executive officer of the company until 1999, when he became chairman. He continued in that role until his retirement in 2016. [3]
Boston Scientific's device, which it plans to launch in the coming months, is a balloon catheter coated with a drug called paclitaxel and is designed to transfer the drug to the vessel wall to ...
Boston Scientific, which makes pacemakers, stents and catheters, will pay $71 in cash per share, representing a 23.3% premium to the Axonics' last close. Axonics' products, such as Axonics R20 and ...
An investigation showed that Boston's device, Obsidio Embolic, when used with a specific technique posed a higher risk of bowel ischemia during procedures to stop gastrointestinal (GI) bleeding ...
The next day, Boston Scientific increased their bid to $25 billion, followed the next day by Johnson & Johnson increasing their bid to $24.2 billion. It was not until January 17 that Boston Scientific produced a new offer of $27.2 billion ($80 per share), with the help of Abbott Laboratories. Abbott agreed to purchase $1.4 billion of Boston ...
Receipt of the CE Mark followed by a limited launch of the WATCHMAN FLX device in Europe is likely to drive top-line contributions from Boston Scientific's (BSX) IC suite.